ABBV Buys Rights to Bretisilocin, a Novel Psychedelic for Depression

AbbVie ABBV has announced a deal with private neuroscience biotech, Gilgamesh Pharmaceuticals, to acquire the latter’s lead pipeline candidate, bretisilocin (GM-2505), a novel therapy being developed for treating major depressive disorder(MDD).Gilgamesh is currently developing bretisilocin, a novel, psychedelic compound, in a phase II study for treating moderate-to-severe MDD. Data from...